(Q43753113)

26 November 2017

title

Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma (English)

1 reference

Hormone Replacement Therapy

26 November 2017

main subject

1 reference

5

Leslie Bernstein

1 reference

26 November 2017

10

Giske Ursin

1 reference

26 November 2017

13

Dennis Deapen

1 reference

26 November 2017

1

Janet R Daling

1 reference

26 November 2017

4

Lynda F Voigt

1 reference

26 November 2017

2

Kathleen E Malone

1 reference

26 November 2017

7

Polly A Marchbanks

1 reference

26 November 2017

3

David R Doody

1 reference

26 November 2017

8

Sandra A Norman

1 reference

26 November 2017

17

Brian L Strom

1 reference

26 November 2017

19

Robert Spirtas

1 reference

26 November 2017

11

Jesse A Berlin

1 reference

26 November 2017

14

Suzanne G Folger

1 reference

26 November 2017

15

Jill A McDonald

1 reference

26 November 2017

18

Phyllis A Wingo

1 reference

26 November 2017

6

Ralph J Coates

1 reference

26 November 2017

Linda K Weiss

9

1 reference

26 November 2017

Ronald T Burkman

series ordinal

12

1 reference

26 November 2017

Michael S Simon

series ordinal

16

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

26 November 2017

1 reference

26 November 2017

volume

95

1 reference

26 November 2017

issue

12

1 reference

26 November 2017

page(s)

2455-2464

1 reference

Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10984

Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10984

7 January 2021

Hormone replacement therapy in relation to breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10984

7 January 2021

Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10984

7 January 2021

The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational results.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10984

7 January 2021

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10984

7 January 2021

Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10984

7 January 2021

Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10984

7 January 2021

Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10984

7 January 2021

Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10984

7 January 2021

Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10984

7 January 2021

Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10984

7 January 2021

More about: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10984

7 January 2021

Influence of age and parity on the development of the human breast

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10984

7 January 2021

Hormonal regulation of apoptosis in breast cells and tissues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10984

7 January 2021

Estradiol and progesterone regulate the proliferation of human breast epithelial cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10984

7 January 2021

The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10984

7 January 2021

Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10984

7 January 2021

Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10984

7 January 2021

Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10984

7 January 2021

Identifiers

DOI

10.1002/CNCR.10984

1 reference

26 November 2017

1 reference